Condition (MeSH)
Chondrosarcoma, Mesenchymal
ClinicalTrials.gov lists 5 trials for Chondrosarcoma, Mesenchymal or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
5 of the 5 trials are tagged with Chondrosarcoma, Mesenchymal itself; the rest are tagged with a narrower condition beneath it.
When did Chondrosarcoma, Mesenchymal trials start? (3)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2021 | 1 |
| 2014 | 3 |
| 2010 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Chondrosarcoma, Mesenchymal trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 4 |
| Phase 2/3 | 1 |
How many Chondrosarcoma, Mesenchymal trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Active, not recruiting | 1 |
| Completed | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Chondrosarcoma, Mesenchymal trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 2 |
| Italian Sarcoma Group | 1 |
Which serious adverse events do Chondrosarcoma, Mesenchymal trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hypophosphatemia | 24 | 2 |
| Febrile neutropenia | 21 | 1 |
| Thromboembolic event | 15 | 3 |
| Hypertension | 14 | 1 |
| Anemia | 13 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Chondrosarcoma, Mesenchymal? (6)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Mesenchymal Chondrosarcoma-A Retrospective study. | The Gulf journal of oncology | 2021 | Yes |
| Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. | BMC cancer | 2016 | Yes |
| Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. | Genes, chromosomes & cancer | 2012 | Yes |
| FLI-1 distinguishes Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma. | Applied immunohistochemistry & molecular morphology : AIMM | 2011 | Yes |
| The clinical approach towards chondrosarcoma. | The oncologist | 2008 | Yes |
Showing 5 of 6 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.